Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock

Critical Care Medicine

Volumn 39, Issue 7, 2011, Pages 1641-1648

  Nakada, Taka Aki ^a   Russell, James A ^a   Boyd, John H ^a   McLaughlin, Luke ^a   Nakada, Emiri ^a   Thair, Simone A ^a   Hirasawa, Hiroyuki ^b   Oda, Shigeto ^b   Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin; critical care; genetics; polymorphisms; septic shock; severe sepsis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II TYPE 1 RECEPTOR ASSOCIATED PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; HORMONE RECEPTOR; LACTIC ACID; NORADRENALIN; UNCLASSIFIED DRUG; VASOPRESSIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DNA EXTRACTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HEART RATE; HUMAN; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; LEUKOCYTE; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79959639640     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318218665a     Document Type: Article

References (41)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310 (Pubitemid 32641789)
2. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
3. Mehta PK, Griendling KK: Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97 (Pubitemid 46127306)
4. Schmieder RE, Hilgers KF, Schlaich MP, et al: Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369:1208-1219 (Pubitemid 46527856)
5. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 2004; 351:159-169
6. Bucher M, Ittner KP, Hobbhahn J, et al: Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension 2001; 38:177-182 (Pubitemid 34224740)
7. Daviet L, Lehtonen JY, Tamura K, et al: Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem 1999; 274:17058-17062
8. Cui T, Nakagami H, Iwai M, et al: ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun 2000; 279: 938-941 (Pubitemid 32042880)
9. Guo DF, Sun YL, Hamet P, et al: The angiotensin II type 1 receptor and receptorassociated proteins. Cell Res 2001; 11: 165-180 (Pubitemid 33677246)
10. Wang W, Huang Y, Zhou Z, et al: Identification and characterization of AGTRAP, a human homolog of murine angiotensin II receptor- associated protein (AGTRAP). Int J Biochem Cell Biol 2002; 34:93-102 (Pubitemid 33152918)
11. Lopez-Ilasaca M, Liu X, Tamura K, et al: The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell 2003; 14:5038-5050 (Pubitemid 37484817)
12. Tanaka Y, Tamura K, Koide Y, et al: The novel angiotensin II type 1 receptor (AT1R)- associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. FEBS Lett 2005; 579:1579-1586 (Pubitemid 40341526)
13. Doerschug KC, Delsing AS, Schmidt GA, et al: Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care 2010; 14:R24
14. Wan L, Langenberg C, Bellomo R, et al: Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009; 13:R190
15. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153
16. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359:995-1003 (Pubitemid 34286536)
17. Yusuf S, Teo KK, Pogue J, et al: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559 (Pubitemid 351522739)
18. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, et al: ACE polymorphisms. Circ Res 2006; 98: 1123-1133 (Pubitemid 43948098)
19. Wu CK, Tsai CT, Chang YC, et al: Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens 2009; 27:502-507
20. Marshall RP, Webb S, Bellingan GJ, et al: Angiotensin converting enzyme insertion/ deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166:646-650 (Pubitemid 34971844)
21. Bunker-Wiersma HE, Koopmans RP, Kuipers TW, et al: Single nucleotide polymorphisms in genes of circulatory homeostasis in surviving pediatric intensive care patients with meningococcal infection. Pediatr Crit Care Med 2008; 9:517-523
22. Cogulu O, Onay H, Uzunkaya D, et al: Role of angiotensin-converting enzyme gene polymorphisms in children with sepsis and septic shock. Pediatr Int 2008; 50:477-480
23. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
24. Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887 (Pubitemid 351397087)
25. Walley KR, Russell JA: Protein C-1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 2007; 35:12-17 (Pubitemid 46035671)
26. Podgoreanu MV, Schwinn DA: New paradigms in cardiovascular medicine: Emerging technologies and practices: Perioperative genomics. J Am Coll Cardiol 2005; 46: 1965-1977
27. Carlson CS, Eberle MA, Rieder MJ, et al: Selecting a maximally informative set of single- nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74:106-120 (Pubitemid 38085242)
28. Slager SL, Schaid DJ: Case- control studies of genetic markers: Power and sample size approximations for Armitage's test for trend. Hum Hered 2001; 52:149-153 (Pubitemid 34701500)
29. Hardy J, Singleton A: Genomewide association studies and human disease. N Engl J Med 2009; 360:1759-1768
30. Balding DJ: A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7:781-791 (Pubitemid 44413222)
31. Devlin B, Roeder K: Genomic control for association studies. Biometrics 1999; 55: 997-1004
32. Devlin B, Roeder K, Wasserman L: Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 2001; 60: 155-166 (Pubitemid 34235086)
33. Wong HR, Cvijanovich N, Allen GL, et al: Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med 2009; 37:1558-1566
34. Rasini E, Cosentino M, Marino F, et al: Angiotensin II type 1 receptor expression on human leukocyte subsets: A flow cytometric and RTPCR study. Regul Pept 2006; 134:69-74
35. Guzik TJ, Hoch NE, Brown KA, et al: Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460 (Pubitemid 47529329)
36. Crowley SD, Frey CW, Gould SK, et al: Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008; 295: F515-F524
37. Oshita A, Iwai M, Chen R, et al: Attenuation of inflammatory vascular remodeling by angiotensin II type 1 receptor-associated protein. Hypertension 2006; 48:671-676 (Pubitemid 44843871)
38. Kawada T, Mizuno M, Shimizu S, et al: Angiotensin II disproportionally attenuates dynamic vagal and sympathetic heart rate controls. Am J Physiol Heart Circ Physiol 2009; 296:H1666-H1674
39. Karas M, Lacourciere Y, LeBlanc AR, et al: Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens 2005; 23: 1251-1260 (Pubitemid 40862730)
40. Qian X, Lu Z, Tan M, et al: A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet 2007; 15:1239-1245 (Pubitemid 350143180)
41. Newton-Cheh C, Johnson T, Gateva V, et al: Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41:666-676